AXSM
Neutral signalScored 2026-09-06 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Axsome Therapeutics, Inc.
- Nom
- Axsome Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $7.7B
- Employés
- 1,346
- PDG
- Herriot Tabuteau
- Site web
- https://www.axsome.com
- Marché
- AVXLDFTXDNLIJAZZNBIXNMRA
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 99 330 titres (~22 470 561,54 $ US)
- Insiders
- TABUTEAU HERRIOT
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$12,624,805
Avg sell (VWAP, 90d window) $211.60 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$12,624,805 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-06
- Last synced
-
2026-08-12 09:47:22
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-03 | Jacobson Mark L. | Sell · S · 10b5-1 | 10,000 | $208.65 | $2,086,500 | Form 4 |
| 2026-08-06 | TABUTEAU HERRIOT | Sell · S · 10b5-1 | 4,660 | $213.95 | $997,007 | Form 4 |
| 2026-08-05 | TABUTEAU HERRIOT | Sell · S · 10b5-1 | 45,004 | $212.01 | $9,541,298 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-06 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
AXSM presents a weak overall profile: a low catalyst score (15) driven by heavy insider selling ($22.47M by the CEO with zero buys) and an earnings miss despite 46% revenue growth signals deteriorating market confidence.
The first sentence of the analysis written for AXSM on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $10.5M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $10.5M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 1.55 · operating margin -27% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 92.6% | 91.4% | 90.4% | 89.6% | 0.0% | |
| Ebit Margin | -27.7% | -72.7% | -85.7% | -359.3% | 0.0% | |
| Ebitda Margin | -26.3% | -70.7% | -83.1% | -350.5% | 0.0% | |
| Operating Profit Margin | -26.5% | -72.7% | -85.7% | -359.3% | 0.0% | |
| Pretax Profit Margin | -28.8% | -74.4% | -88.1% | -374.0% | 0.0% | |
| Continuous Operations Profit Margin | -28.7% | -74.5% | -88.4% | -374.0% | 0.0% | |
| Net Profit Margin | -28.7% | -74.5% | -88.4% | -374.0% | 0.0% | |
| Bottom Line Profit Margin | -28.7% | -74.5% | -88.4% | -374.0% | 0.0% | |
| Current Ratio | 1.555 | 2.108 | 3.632 | 2.544 | 3.751 | |
| Quick Ratio | 1.481 | 2.040 | 3.523 | 2.499 | 3.751 | |
| Solvency Ratio | -0.289 | -0.546 | -0.585 | -0.823 | -1.806 | |
| Cash Ratio | 0.852 | 1.370 | 2.781 | 2.080 | 3.749 | |
| Price To Earnings Ratio | -49.630 | -14.125 | -15.102 | -16.767 | -10.888 | |
| Price To Earnings Growth Ratio | 1.287 | -1.034 | -1.037 | -0.515 | -0.481 | |
| Forward Price To Earnings Growth Ratio | 1.287 | -1.034 | -1.037 | -0.515 | -0.481 | |
| Price To Earnings Diluted Ratio | -49.630 | -14.125 | -15.102 | -16.767 | -10.888 | |
| Price To Earnings Diluted Growth Ratio | 1.287 | -1.034 | -1.037 | -0.515 | -0.481 | |
| Price To Book Ratio | 102.903 | 71.104 | 18.931 | 28.623 | 90.928 | |
| Price To Sales Ratio | 14.230 | 10.511 | 13.361 | 62.669 | 0.000 | |
| Price To Free Cash Flow Ratio | -96.776 | -31.505 | -24.820 | -26.753 | -13.095 | |
| Price To Operating Cash Flow Ratio | -97.273 | -31.571 | -24.920 | -26.914 | -13.132 | |
| Debt To Assets Ratio | 0.350 | 0.339 | 0.317 | 0.286 | 0.566 | |
| Debt To Equity Ratio | 2.733 | 3.384 | 0.976 | 0.864 | 3.180 | |
| Debt To Capital Ratio | 0.732 | 0.772 | 0.494 | 0.464 | 0.761 | |
| Long Term Debt To Capital Ratio | 0.615 | 0.760 | 0.483 | 0.462 | 0.758 | |
| Financial Leverage Ratio | 7.813 | 9.971 | 3.080 | 3.026 | 5.616 | |
| Working Capital Turnover Ratio | 2.746 | 1.243 | 1.052 | 0.471 | 0.000 | |
| Operating Cash Flow Ratio | -0.247 | -0.558 | -1.045 | -1.207 | -4.692 | |
| Operating Cash Flow Sales Ratio | -0.146 | -0.333 | -0.536 | -2.328 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | 1.002 | 1.004 | 1.006 | 1.003 | |
| Debt Service Coverage Ratio | -2.107 | -41.511 | -35.015 | -23.912 | -21.880 | |
| Interest Coverage Ratio | -25.810 | -42.710 | -35.925 | -24.512 | -21.894 | |
| Short Term Operating Cash Flow Coverage Ratio | -1.280 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.387 | -0.665 | -0.778 | -1.231 | -2.177 | |
| Capital Expenditure Coverage Ratio | -194.594 | -475.593 | -249.278 | -165.970 | -351.383 | |
| Dividend Paid And Capex Coverage Ratio | -194.594 | -475.593 | -249.278 | -165.970 | -351.383 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -53.570 | -14.422 | -15.181 | -17.273 | -11.109 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 92.6% | ▲1.2% | ▲19.8% |
| Ebit Margin | -27.7% | ▲45.0% | ▲81.3% |
| Ebitda Margin | -26.3% | ▲44.4% | ▲79.8% |
| Operating Profit Margin | -26.5% | ▲46.2% | ▲82.3% |
| Pretax Profit Margin | -28.8% | ▲45.7% | ▲84.3% |
| Continuous Operations Profit Margin | -28.7% | ▲45.8% | ▲84.4% |
| Net Profit Margin | -28.7% | ▲45.8% | ▲84.4% |
| Bottom Line Profit Margin | -28.7% | ▲45.8% | ▲84.4% |
| Current Ratio | 1.555 | ▼-0.553 | ▼-1.163 |
| Quick Ratio | 1.481 | ▼-0.559 | ▼-1.178 |
| Solvency Ratio | -0.289 | ▲0.257 | ▲0.521 |
| Cash Ratio | 0.852 | ▼-0.518 | ▼-1.314 |
| Price To Earnings Ratio | -49.630 | ▼-35.505 | ▼-28.328 |
| Price To Earnings Growth Ratio | 1.287 | ▲2.321 | ▲1.643 |
| Forward Price To Earnings Growth Ratio | 1.287 | ▲2.321 | ▲1.643 |
| Price To Earnings Diluted Ratio | -49.630 | ▼-35.505 | ▼-28.328 |
| Price To Earnings Diluted Growth Ratio | 1.287 | ▲2.321 | ▲1.643 |
| Price To Book Ratio | 102.903 | ▲31.799 | ▲40.405 |
| Price To Sales Ratio | 14.230 | ▲3.719 | ▼-5.924 |
| Price To Free Cash Flow Ratio | -96.776 | ▼-65.272 | ▼-58.186 |
| Price To Operating Cash Flow Ratio | -97.273 | ▼-65.703 | ▼-58.511 |
| Debt To Assets Ratio | 0.350 | ▲0.010 | ▼-0.022 |
| Debt To Equity Ratio | 2.733 | ▼-0.651 | ▲0.505 |
| Debt To Capital Ratio | 0.732 | ▼-0.040 | ▲0.088 |
| Long Term Debt To Capital Ratio | 0.615 | ▼-0.145 | ▼-0.001 |
| Financial Leverage Ratio | 7.812 | ▼-2.159 | ▲1.911 |
| Working Capital Turnover Ratio | 2.746 | ▲1.502 | ▲1.643 |
| Operating Cash Flow Ratio | -0.247 | ▲0.311 | ▲1.303 |
| Operating Cash Flow Sales Ratio | -0.146 | ▲0.187 | ▲0.522 |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | ▲0.003 | ▲0.001 |
| Debt Service Coverage Ratio | -2.107 | ▲39.405 | ▲22.779 |
| Interest Coverage Ratio | -25.810 | ▲16.900 | ▲4.360 |
| Short Term Operating Cash Flow Coverage Ratio | -1.280 | ▼-1.280 | ▼-1.024 |
| Operating Cash Flow Coverage Ratio | -0.387 | ▲0.278 | ▲0.661 |
| Capital Expenditure Coverage Ratio | -194.594 | ▲280.999 | ▲92.770 |
| Dividend Paid And Capex Coverage Ratio | -194.594 | ▲280.999 | ▲92.770 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -53.570 | ▼-39.148 | ▼-31.259 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $9.09B | $4.05B | $3.62B | $3.14B | $1.42B | |
| Enterprise value | $9.00B | $3.93B | $3.42B | $3.03B | $1.38B | |
| EV / Sales | 14.10x | 10.19x | 12.62x | 60.55x | 0.00x | |
| EV / Op. cash flow | -96.40x | -30.62x | -23.54x | -26.00x | -12.79x | |
| EV / Free cash flow | -95.91x | -30.55x | -23.45x | -25.85x | -12.76x | |
| EV / EBITDA | -53.57x | -14.42x | -15.18x | -17.27x | -11.11x | |
| Net debt / EBITDA | 0.49x | 0.45x | 0.89x | 0.60x | 0.29x | |
| Current ratio | 1.55x | 2.11x | 3.63x | 2.54x | 3.75x | |
| Income quality | 0.51x | 0.45x | 0.61x | 0.62x | 0.83x | |
| Graham net-net | -$2 | -$2 | $1 | $0 | $0 | |
| Tax burden | 99.7% | 100.0% | 100.4% | 100.0% | 100.0% | |
| Interest burden | 103.7% | 102.3% | 102.8% | 104.1% | 104.6% | |
| Working capital | $210.2M | $255.0M | $365.4M | $149.1M | $63.5M | |
| Invested capital | $283.6M | $319.9M | $438.4M | $220.2M | $64.4M | |
| Return on assets | -26.6% | -50.5% | -40.7% | -56.5% | -148.5% | |
| Operating ROA | -26.9% | -48.5% | -50.4% | -85.8% | -91.1% | |
| Return on tangible assets | -28.7% | -56.4% | -45.8% | -71.6% | -148.5% | |
| Return on equity | -207.5% | -503.8% | -125.3% | -170.8% | -834.3% | |
| Return on invested capital | -44.0% | -82.1% | -51.4% | -76.4% | -190.9% | |
| Return on capital employed | -54.4% | -82.9% | -51.6% | -76.5% | -192.7% | |
| Earnings yield | -2.0% | -7.1% | -6.6% | -6.0% | -9.2% | |
| Free cash flow yield | -1.0% | -3.2% | -4.0% | -3.7% | -7.6% | |
| Capex / Op. cash flow | -0.5% | -0.2% | -0.4% | -0.6% | -0.3% | |
| Capex / Depreciation | 5.3% | 3.4% | 8.5% | 15.9% | 405.3% | |
| Capex / Sales | 0.1% | 0.1% | 0.2% | 1.4% | 0.0% | |
| SG&A / Sales | 89.4% | 106.7% | 119.4% | 318.3% | 0.0% | |
| R&D / Sales | 28.7% | 48.5% | 36.2% | 115.8% | 0.0% | |
| Stock comp / Sales | 14.7% | 22.1% | 23.1% | 75.4% | 0.0% | |
| Intangibles / Total assets | 7.6% | 10.4% | 11.1% | 21.1% | 0.0% | |
| Days sales outstanding | 128d | 134d | 128d | 275d | 0d | |
| Days payables outstanding | 504d | 789d | 570d | 2711d | 0d | |
| Operating cycle | 343d | 307d | 340d | 578d | 0d | |
| Cash conversion cycle | -161d | -482d | -230d | -2132d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-11 Axsome''s Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues AXSM''s Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.
- 2026-08-11 Axsome Therapeutics Q2 Earnings Review: I Just Can''t See The Value Proposition Axsome Therapeutics, Inc. reported Q2 2026 net product revenue growth of 46% year-on-year, but rising SG&A costs mostly offset commercial gains. Auvelity drove most revenues, benefiting from new Alzheimer''s agitation indication and expanded sales force, yet profitability remains elusive. Management reiterates ambitious ~$8bn peak sales target for Auvelity, but current revenue trajectory and market dynamics cast doubt on achievability.
- 2026-08-10 Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript
- 2026-08-10 Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 2026-08-10 Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimates Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.99 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.92 per share a year ago.
- 2026-08-10 Axsome Therapeutics Q2 Earnings Call Highlights Axsome Therapeutics NASDAQ: AXSM reported second-quarter 2026 net product revenue of $218 million, up 46% from a year earlier, as sales of AUVELITY and SUNOSI increased and prescription demand for SYMBRAVO continued to build.
- 2026-08-10 Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth SUNOSI® 2Q 2026 net product revenue of $35.8 million, representing 20% year-over-year growth SYMBRAVO® 2Q 2026 net product sales of $2.3 million AUVELITY launched for treatment of agitation associated with dementia due to Alzheimer''s disease in June 2026 NDA submission for AXS-12 for cataplexy in narcolepsy accepted by the FDA with PDUFA target action date of May 1, 2027 FOCUS-2 and FOCUS-3 Phase 3 trials of solriamfetol in children and adolescents with ADHD initiated Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the second quarter of 2026 and provided a general business update. “The second quarter was highly productive for Axsome.
- 2026-08-10 Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $997,007.00 in Stock Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) CEO Herriot Tabuteau sold 4,660 shares of the business''s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $213.95, for a total value of $997,007.00. Following the completion of the transaction, the chief executive officer directly owned 7,229 shares
- 2026-08-08 Assenagon Asset Management S.A. Cuts Stock Holdings in Axsome Therapeutics, Inc. $AXSM Assenagon Asset Management S.A. lowered its holdings in Axsome Therapeutics, Inc. (NASDAQ: AXSM) by 47.5% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 454,682 shares of the company''s stock after selling 411,276 shares during the quarter. Assenagon Asset Management S.A.
- 2026-08-05 Countdown to Axsome (AXSM) Q2 Earnings: Wall Street Forecasts for Key Metrics Looking beyond Wall Street''s top-and-bottom-line estimate forecasts for Axsome (AXSM), delve into some of its key metrics to gain a deeper insight into the company''s potential performance for the quarter ended June 2026.